Biote Reports Fourth Quarter and Full Year 2024 Financial Results Strengthened business with launch of BioteRx and enhancements to Biote Method Provides fiscal 2025 outlook IRVING, TX

Biote Reports Fourth Quarter and Full Year 2024 Financial Results

Strengthened business with launch of BioteRx and enhancements to Biote Method

Provides fiscal 2025 outlook

March 12, 2025 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth

quarter and full year ended December 31, 2024.

Fourth Quarter 2024 Financial Highlights

(All financial result comparisons made are against the prior-year period)

Full Year 2024 Financial Highlights

(All financial result comparisons made are against the prior year)

In 2024 Biote strengthened its capabilities to provide the

next level of individualized and evidence-based healthcare, said Bob Peterson, Biote Chief Financial Officer. Full year 2024 revenue increased 6.4% compared to 2023 and, with continued efficiencies from the vertical integration of our

503B manufacturing facility, gross profit margin also improved. Even as fourth quarter procedure volume was impacted due to the transition to upgraded clinical decision support software throughout our network, fourth quarter revenue increased 9.0%.

We are continuing to work closely with our practitioners and are offering additional training on our enhanced software. We ended the year in a strong financial position, with $39.3 million in cash and cash equivalents on our balance

Bret Christensen, Biote Chief Executive Officer, stated, Over the past fifteen months, Biote achieved

significant progress, which we believe will help us succeed in building a strong foundation for growth in the years ahead. With the phased launch of the BioteRx platform and the roll-out of our upgraded

clinical decision support software, we strengthened our competitive moat and broadened our capabilities to more comprehensively address the growing market for hormone optimization and therapeutic wellness. Additionally, we continued our efforts to

optimize our manufacturing efficiency and strengthen our supply chain through the integration and growth of Asteria Health. Biote continues to generate strong operating cash flow while also investing in future growth.

2024 Fourth Quarter Financial Review

result comparisons made are against the prior-year period unless otherwise noted)

Revenue for the fourth quarter of 2024 was $49.8 million, an

increase of 9.0% from $45.7 million for the fourth quarter of 2023. Procedure revenue grew 5.0%, primarily reflecting growth at established top-tier clinics. As expected, fourth quarter procedure revenue

growth was negatively impacted by two headwinds: 1) a reduction in procedure volume as clinics transitioned to our upgraded clinical decision support software introduced in the third quarter of 2024; and 2) our focus on training our existing

practitioners, which impacted our ability to add new clinics at the expected rate. Dietary supplement revenue grew 10.2%, benefiting from the transition of a portion of this business to our e-commerce platform

Gross profit margin for the fourth quarter of 2024 was 71.8% compared to 69.4% for the fourth quarter of 2023. The increase in gross profit

margin was primarily due to the vertical integration of our 503B manufacturing facility and effective cost management.

Operating income for the fourth

quarter of 2024 was $2.8 million, compared to $5.5 million for the fourth quarter of 2023. Operating income in the fourth quarter of 2024 decreased due to employee-related investments and additional legal expenses.

Net income for the fourth quarter of 2024 was $3.5 million and diluted earnings per share attributable to biote Corp. stockholders of $0.10, compared to

net income of $12.1 million and diluted earnings per share attributable to biote Corp. stockholders of $0.18. Net income for the fourth quarter of 2024 and 2023 included a loss of $0.8 million and a gain of $5.4 million, respectively,

due to a change in the fair value of the earnout liabilities.

Adjusted EBITDA for the fourth quarter of 2024 was $15.1 million, with an Adjusted

EBITDA margin of 30.3%, compared to Adjusted EBITDA of $13.6 million, with an Adjusted EBITDA margin of 29.7%. The increases in Adjusted EBITDA and Adjusted EBITDA margin for the fourth quarter of 2024 reflected the operating leverage in our

2024 Full Year Financial Review

(All financial result comparisons made are against the prior year unless otherwise noted)

Revenue for 2024 was $197.2 million, an increase of 6.4% from $185.4 million in 2023. The increase was primarily driven by growth in procedure

Gross profit margin for 2024 was 70.5% compared to 68.8% for 2023. The increase in gross profit margin was

primarily due to the vertical integration of our 503B manufacturing facility and effective cost management.

Operating income for 2024 was

$31.6 million, an increase of 10.3% compared to operating income of $28.7 million for 2023. Operating income improved in 2024 primarily due to revenue growth and higher gross profit, which more than offset higher operating expenses.

Net income for 2024 was $0.05 million and diluted earnings per share attributable to biote Corp. stockholders of $0.09, compared to net loss of $(2.8)

million and diluted earnings per share attributable to biote Corp. shareholders of $0.13 in 2023.

Adjusted EBITDA for 2024 was $58.2 million, with

an Adjusted EBITDA margin of 29.5%, compared to Adjusted EBITDA of $55.3 million, with an Adjusted EBITDA margin of 29.8% for 2023.

To reach our full potential and drive accelerated growth, I have identified several areas of emphasis for 2025 which I believe

are fundamental to commercial execution at a high level, said Mr. Christensen. First, we are strengthening our efforts to maximize the value of our top-tier providers. Second, we are

intensifying our focus on adding practitioners to further broaden our network and reinvigorate our procedure revenue growth rate. Third, we are working to drive revenue growth by strengthening accountability and improving consistency and discipline

throughout the commercial organization. Although these changes are expected to be implemented quickly, they will take time to show results before we experience an anticipated acceleration in revenue growth. I m confident that these initiatives

will strengthen our commercial organization through increased productivity beginning later this year.

The Company expects the following for fiscal

Although we do not typically provide quarterly financial guidance, we expect

first quarter 2025 revenue to be slightly higher as compared to the first quarter of 2024 as we ramp up training and onboarding of new practitioners to reinvigorate quickstart-related revenue. First quarter 2025 Adjusted EBITDA is expected to be

approximately 5 percent lower as compared to the first quarter of 2024 due to increased sales and marketing activities to reaccelerate new customer growth.

Biote management will host a conference call to review these results and provide a business update beginning at 5:00 p.m. ET on Tuesday, March 12, 2025.

To access the conference call by telephone, please dial (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). To access a live webcast of the call,

interested parties may use the following link: Biote Fourth Quarter 2024 Earnings Conference Call. A replay of the webcast will be available on the Events page of the Biote Investor Relations website, at ir.biote.com, shortly after the

Discussion of Non-GAAP Financial Measures

To provide investors with additional information regarding our financial results, Biote has disclosed Adjusted EBITDA, a

non-GAAP financial measure that it calculates as net income before interest, taxes and depreciation and amortization, further adjusted to exclude stock-based compensation, litigation expenses, legal

settlements, transaction-related expenses, merger and acquisition expenses, fair value adjustments to certain equity instruments classified as liabilities and other expenses. Below we have provided a reconciliation of Adjusted EBITDA to net income,

the most directly comparable GAAP financial measure.

We present Adjusted EBITDA and Adjusted EBITDA margin because it is a key measure used by our

management to evaluate our operating performance, generate future operating plans and determine payments under compensation programs. Accordingly, we believe that Adjusted EBITDA and Adjusted EBITDA margin provide useful information to investors and

others in understanding and evaluating our operating results in the same manner as our management.

Adjusted EBITDA and Adjusted EBITDA margin have

limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are as follows:

In addition, Adjusted EBITDA and Adjusted EBITDA margin are subject to inherent limitations as it reflects the

exercise of judgment by Biote s management about which expenses are excluded or included. A reconciliation is provided in the financial statement tables included below in this press release for each

non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Because of these limitations, you should consider Adjusted EBITDA and Adjusted EBITDA margin

alongside other financial performance measures, including net income and our other GAAP results.

Forward-Looking Non-GAAP Financial Measures

The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to their comparable GAAP

financial measures because it could not do so without unreasonable effort due to the unavailability of certain information needed to calculate reconciling items. For example, the Company has not included a reconciliation of projected Adjusted EBITDA

to GAAP net income (loss), which is the most directly comparable GAAP measure, for the periods presented in reliance on the unreasonable efforts exception provided under Item 10(e)(1)(i)(B) of Regulation S-K.

The Company s projected Adjusted EBITDA excludes certain items that are inherently uncertain and difficult to predict including, but not limited to, share-based compensation expense, income taxes, due diligence expenses and legal expenses. Due

to the variability, complexity and limited visibility of the adjusting items that would be excluded from projected Adjusted EBITDA in future periods, management does not forecast them for internal use and therefore cannot create a quantitative

projected Adjusted EBITDA to GAAP net income (loss) reconciliation for the periods presented without unreasonable efforts. A quantitative reconciliation of projected Adjusted EBITDA to GAAP net income (loss) for the periods presented would imply a

degree of precision and certainty as to these future items that does not exist and could be confusing to investors. From a qualitative perspective, it is anticipated that the differences between projected Adjusted EBITDA to GAAP net income (loss)

for the periods presented will consist of items similar to those described in the financial tables later in this release, including, for example and without limitation, share-based compensation expense, income taxes, due diligence expenses and legal

expenses. The timing and amount of any of these excluded items could significantly impact the Company s GAAP net income (loss) for a particular period. When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis.

Biote is transforming healthy aging through innovative, personalized hormone optimization and therapeutic wellness solutions delivered by Biote-certified

medical providers. Biote trains practitioners to identify and treat early indicators of aging conditions, an underserved global market, providing affordable symptom relief for patients and driving clinic success for practitioners.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and

Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words may,

can, should, will, estimate, plan, project, forecast, intend, expect, anticipate, hope, believe,

seek, target, continue, could, might, ongoing, potential, predict, would and other similar expressions, are intended to identify

forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many

factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the success of our dietary supplements to attain significant market acceptance

among clinics, practitioners and their patients; our customers reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers; our and our customers

sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; our ability to

grow our business; the significant competition we face in our industry; the impact of strategic acquisitions and the implementation of our growth strategies; our limited operating history; our ability to protect our intellectual property; the heavy

regulatory oversight in our industry; changes in applicable laws or regulations; changes to international tariffs; the inability to profitably expand in existing markets and into new markets; the possibility that we may be adversely impacted by

other economic, business and/or competitive factors, including the impact of hurricane and other natural disasters; and future exchange and interest rates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing

factors and other risks and uncertainties described in the Risk Factors section of the Biote s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, each filed or to be

filed with the Securities and Exchange Commission (the SEC ) and other documents filed by Biote from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and

results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Biote assumes

no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Biote does not give any assurance that it will achieve its expectations.

Consolidated Balance